Joined August 2018
- Tweets 2,542
- Following 372
- Followers 3,737
- Likes 1,739
265 Photos and videos
Pinned Tweet
8 Apr 2024
OK, this one is really meaningful for our whole team. Our preclinical paper on pan-RAS inhibition in pancreatic cancer is now online @Nature. Led by OliveLab student @ulawasko and Revolution Medicines colleagues JingJing Jiang and Mallika Singh. nature.com/articles/s41586-0…
19
57
220
29,967
23 Nov 2024
Sad to miss the first #PCAMChat24. Briefly, this is Ken Olive from @columbiacancer. I lead a translational research lab dedicated to #PDAC research. Excited to join in for part 2!
10
680
14 Nov 2024
Suddenly seeing a huge number of fellow scientists show up on BlueSky. FYI I'm one of them. Come follow me: @kenolivelab.bsky.social
2
5
515
KenOliveLab retweeted
4 Nov 2024
ICYMI, the new issue of @CR_AACR is online and features the print version of the In Focus commentary
#PancreaticCancer–Associated Fibroblasts: Where Do We Go from Here?
aacrjournals.org/cancerres/a…
By Eileen Carpenter, @DebVendramini @MC_Hasselluhn @MaraShermanLab @Pasca_Lab @ednacukierman @KenOliveLab
13
36
5,043
1 Nov 2024
New post on our website with updated information on the clinical development of RAS inhibitors for pancreatic cancer. I'll summarize on twitter sooner, but here's the full version: olivelab.org/ras-inhibitor-2…
1
14
43
4,180
KenOliveLab retweeted
29 Oct 2024
On behalf of our Phase I program @columbiacancer , proud of @bherzbergmd presenting exciting initial data on IDE397 in MTAP-del tumors at the
@EORTC - @theNCI - @AACR conference ir.ideayabio.com/2024-10-25-… We are excited to offer this study to our patients recruit.cumc.columbia.edu/st…
1
6
50
4,408
25 Oct 2024
Really excited for my postdoc @MC_Hasselluhn who received a 4th percentile score on her K99 application. Folks, she's on the job market!
9
1
66
13,003
KenOliveLab retweeted
20 Oct 2024
Revolution Medicines has launched its ph 3 study of RMC-6236 (RASolute 302) in patients with previously treated #PancreaticCancer. 1:1 randomization against physician’s choice of chemotherapy. A registration trial for KRAS inhibitor in pancreatic cancer!
clinicaltrials.gov/study/NCT…
4
55
149
20,484
KenOliveLab retweeted
1 Oct 2024
There is a new tool on BioIcons to turn any protein (in PDB format) into a 2D vector illustration in SVG format. You can upload any PDB file or import from PDB, AlphaFoldDB or ESMFoldDB. Feedback welcome :)
bioicons.com/pdb2vector/
19
172
779
58,121
KenOliveLab retweeted
We are thrilled to welcome Michel Sadelain, MD, PhD, a global pioneer in CAR-T therapies, to Columbia and the HICCC.
30 Sep 2024
Columbia welcomes CAR-T pioneer Michel Sadelain, MD, PhD, as the inaugural director of the new Columbia Initiative for Cell Engineering and Therapy and director of the Cancer Cell Therapy Initiative at the Herbert Irving Comprehensive Cancer Center.
➡️columbiamed.link/3zCR9iI
ALT Columbia welcomes Michel Sadelain, MD, PhD, Director of the Columbia Initiative for Cell Engineering and Therapy and director of the Cancer Cell Therapy Initiative in the Herbert Irving Comprehensive Cancer Center.
3
7
58
11,233
KenOliveLab retweeted
17 Sep 2024
I am excited to see this story by my talented Master's Student, Kristina Høj. Her research dives into age-related decline in pancreas regeneration and how it’s linked to a proinflammatory response to injury. @AGA_GHAdvances,@UCPH_BRIC, tinyurl.com/4e2uz2sb
2
2
14
1,349
KenOliveLab retweeted
16 Sep 2024
New online perspective article @CR_AACR article timed with the ongoing #PancreaticCancer stroma session at #AACRPan24
Pancreatic Cancer-Associated Fibroblasts: Where do we go from here?
A conversation with three experts on the PDAC stroma (@MaraShermanLab @ednacukierman & @Pasca_Lab) led by three fantastic early career faculty (@MC_Hasselluhn @DebVendramini & Eileen Carpenter @UMICHpancreas). Lots of great perspectives on this complex subject!
aacrjournals.org/cancerres/a…
14
36
6,251
4 Sep 2024
Hiring committees take note...
2 Sep 2024
That feeling when you submit your first application for a tenure-track faculty! 🧑🔬 I am planing to create a "Translational systems oncology" laboratory focused on cell states, hypoxia and targeted therapies where I will use both wet and dry approaches. #faculty #academiclife
11
1,328
Congratulations to CU-DLDRC Associate Director, Timothy Wang, MD, who is the new Vice Chair for Academic Programs for the Department of Medicine at the Vagelos College of Physicians and Surgeons! Dr Wang will add this new role to his portfolio effective September 3rd, 2024.
1
15
903
KenOliveLab retweeted
22 Aug 2024
@NwosuLab @CornellMBG has opened a call for postdoc applicants. Please kindly repost and or forward to potential applicants.
Job posting: academicjobsonline.org/ajo/j…
Lab website: nwosulab.com
9
12
1,820
KenOliveLab retweeted
22 Aug 2024
Proud to have helped launch the Columbia Early Onset Colorectal Cancer Program @columbiacancer @nyp with @BDionigiMD and Yoanna Pumpalova.
cancer.columbia.edu/early-on…
4
15
1,871
14 Aug 2024
The Olive Lab is looking for a postdoc to lead our translational program on RAS inhibition in pancreatic cancer. Should have exceptional scientific and project management skills, and experience with transdisciplinary research. Must be a good human. olivelab.org
2
38
84
12,130
15 Jul 2024
They present a preliminary design of a planned Phase 3 trial in 2nd line PDAC patients, randomized to physician's choice.
2
2
11
2,887
15 Jul 2024
Really exciting times for the PDAC field, offering real hope for patients. This is just monotherapy. Can't wait to see combinations!
1
15
2,295
15 Jul 2024
Stunning interim clinical trial data from Revolution Medicines... PFS = 8.1 mo in 2nd line KRAS G12-mutant metastatic #PDAC. OS not yet reached, but already more than a year! Benchmark PFS for this group is 2-3.5 months, behnchmark OS is 6.1-6.9. 1/
8
85
246
113,064
15 Jul 2024
All standard caveats apply: single arm data, non randomized, highly scrutinized patients, early phase, selected group, etc. Even with the caveats, the results are exciting IMHO.
1
1
19
2,933